Pharmaceutical-grade sourcing. Clinician-guided dosing.
Pharmaceutical-grade compounded methylene blue with medication screening and clinician-directed dosing.
About 10 minutes. No charge unless your clinician approves.
Interesting mechanism. Serious interaction profile.
Methylene blue has been part of medicine and laboratory science for more than a century. Its longevity-era relevance comes from a much newer conversation: research examining the compound in mitochondrial electron transport, the chain cells use to move electrons during energy production.
That mechanism is interesting without establishing a benefit for memory, focus, energy, or lifespan.
The reason this product belongs inside prescription care is just as important as the reason people read about it. Methylene blue has meaningful medication interactions and can be unsafe in specific conditions. Serotonergic medications and G6PD deficiency are not footnotes to a wellness compound. They can change whether the prescription belongs in your plan at all.
Compounding gives your clinician a way to prescribe an individualized oral formulation when off-label use is judged appropriate, with the rest of your medications and health history reviewed before the prescription moves forward.
The strange and serious parts deserve plain language. Pharmaceutical-grade sourcing, blue discoloration, G6PD screening, and SSRI or serotonin interactions are part of responsible medical use, not details to discover after the prescription arrives.
Read the evidence →For the person who would only consider methylene blue medically.
The Precision-Minded Reader
You have seen methylene blue sold in places that make the molecule look far more casual than it is. You want the version that begins with a prescription decision, not a bottle sourced on trust.
The Safety-Serious Reader
The mitochondrial mechanism caught your attention, but the interaction profile is why you will not treat methylene blue like a supplement. You want the science and the medication review considered together.
The Carefully Medicated Patient
You take other prescriptions and know that interactions can matter more than the headline benefit. You want someone to review the full medication list before the molecule gets anywhere near the plan.
Compounded methylene blue is not an FDA-approved drug product. A licensed provider reviews everything you take, especially antidepressants and other serotonergic medications, and determines whether you are a candidate at all.
This might not be the right fit if:
- Current use of serotonergic medications including SSRIs, SNRIs, or MAOIs, given the risk of serotonin syndrome
- G6PD deficiency, where methylene blue can trigger hemolysis
- Pregnancy or breastfeeding
- Known hypersensitivity to methylene blue
- Significant kidney impairment without specialist oversight
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Methylene Blue, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Mitochondrial electron transport described as a mechanism, not an outcome promise
- Compounded oral formulation prepared to your individual prescription
- Medication and medical history reviewed before prescribing
- Serotonergic medications and G6PD deficiency screened before treatment
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Longevity.
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
Tirzepatide + B12 Microdose
Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care. (Contains tirzepatide and vitamin B12.)
Metformin ER
Diabetes made it famous. Longevity made it interesting again.
FDA-approved generic metformin ER with decades of metabolic use and a serious place in the longevity conversation.
What the research shows
The approved product is an injection for acquired methemoglobinemia.
The detail
The FDA-approved methylene blue product is an injection, and its approved indication is the treatment of acquired methemoglobinemia in pediatric and adult patients, given as 1 mg per kilogram intravenously over 5 to 30 minutes; the efficacy behind that approval was established in 31 adult patients with acquired methemoglobinemia, studied across a prospective open-label single-arm trial and a prospective multicenter observational registry.1
A single oral dose raised fMRI response and correct answers on a memory task.
The detail
In a randomized, double-blind, placebo-controlled trial in 26 healthy adults aged 22 to 62, a single 280 mg oral dose of USP methylene blue increased functional MRI response during a sustained-attention task and a short-term memory task one hour after dosing, and was associated with a 7 percent increase in correct responses during memory retrieval.23
In bipolar disorder, depression and anxiety improved, but cognitive symptoms did not.
The detail
In a 6-month double-blind crossover trial in 37 patients with bipolar disorder already treated with lamotrigine, methylene blue at an active dose of 195 mg daily improved symptoms of depression and anxiety compared with a 15 mg control dose, while its effects on cognitive symptoms were not statistically significant.4
In cells and rodents, methylene blue acted as an alternative mitochondrial electron carrier.
The detail
In cultured neuronal cells and in rodent models of Parkinson disease and transient focal cerebral ischemia, methylene blue acted as an alternative mitochondrial electron carrier, accepting electrons from NADH and transferring them to cytochrome c to bypass blockade of complexes I and III.5
In cultured human cells, lifespan extended by more than 20 population doublings.
The detail
In cultured human IMR90 fibroblasts, nanomolar methylene blue extended the culture lifespan by more than 20 population doublings, increased mitochondrial complex IV by 30 percent and raised cellular oxygen consumption by 37 to 70 percent.6
What it does not show
No approved indication for cognition, focus, energy, mitochondrial function or aging.
The detail
The approved indication and the reason people are interested in this molecule are not the same thing. No FDA-approved methylene blue product carries an indication for cognition, focus, energy, mitochondrial function or aging, the approved product is an injection used for acquired methemoglobinemia, and a compounded oral preparation is not an FDA-approved drug product.1
Oral dosing produced far lower exposure than intravenous dosing of the same 100 mg.
The detail
Route and dose do not carry over. In seven volunteers given 100 mg of methylene blue by both routes, the area under the whole-blood concentration-time curve after oral dosing was 9 nmol/min/mL compared with 137 nmol/min/mL after intravenous dosing, and in the rat arm of the same study intraduodenal dosing produced lower brain concentrations than intravenous dosing.7
No trial has tested oral methylene blue taken daily for memory, focus or energy.
The detail
The human cognitive signal is a single dose, measured one hour later, in 26 people, largely by brain imaging. No randomized trial has tested oral methylene blue taken daily over weeks or months for memory, focus, energy or any aging-related outcome in healthy adults, and the one trial that did run six months, in patients with bipolar disorder, found no significant effect on cognitive symptoms.24
Tested at scale in Alzheimer’s disease, a related compound showed no benefit.
The detail
Where a methylthioninium compound was tested at scale, it did not work. In a 15-month randomized, controlled, double-blind, parallel-arm phase 3 trial at 115 sites in 891 patients with mild to moderate Alzheimer’s disease, leuco-methylthioninium, a stable reduced form of the methylthioninium moiety in methylene blue, showed no benefit on either co-primary endpoint at either dose tested.8
- FDA-approved prescribing information, PROVAYBLUE (methylene blue) injection, American Regent, Inc., label published May 2025.DailyMed
- Rodriguez P, Zhou W, Barrett DW, et al. Multimodal randomized functional MR imaging of the effects of methylene… Radiology. 2016.
- Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity…ClinicalTrials.gov
- Alda M, McKinnon M, Blagdon R, et al. Methylene blue treatment for residual symptoms of bipolar disorder… Br J Psychiatry. 2017.
- Wen Y, Li W, Poteet EC, et al. Alternative mitochondrial electron transfer as a novel strategy for… J Biol Chem. 2011.
- Atamna H, Nguyen A, Schultz C, et al. Methylene blue delays cellular senescence and enhances key… FASEB J. 2008.
- Peter C, Hongwan D, Küpfer A, Lauterburg BH. Pharmacokinetics and organ distribution of intravenous and oral… Eur J Clin Pharmacol. 2000.
- Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients… Lancet. 2016.
The interaction is the headline. Methylene blue inhibits monoamine oxidase, and the approved injectable product carries a boxed warning about serotonin syndrome when it is combined with SSRIs, SNRIs, MAOIs, opioids or dextromethorphan; some reported cases were fatal, and the labeling advises avoiding serotonergic medicines for 72 hours after the last dose.
Do not use if you have
- Contraindicated in G6PD deficiency, because it can cause hemolysis
Commonly reported
- It turns urine, and sometimes stools, blue to blue-green while interfering with pulse oximetry readings and urine dipstick tests
- Headache
- Nausea
- Diarrhea
- Dizziness
- Sensitivity to light
- Shifts in potassium and magnesium
Your provider goes through your full medication list, including over-the-counter cough preparations, and screens for G6PD deficiency and kidney impairment before prescribing, because that safety record comes from the approved injectable used for methemoglobinemia and not from oral methylene blue taken this way.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Serotonin syndrome is the major interaction concern when methylene blue is combined with serotonergic medications, and G6PD deficiency can create serious risk. Blue-green urine and gastrointestinal upset can also occur. Share every medication and relevant condition in your Assessment so those issues can be reviewed before prescribing.
After clinician approval, the pharmacy prepares the compounded prescription for fulfillment.
Methylene blue has approved medical uses, but its use in this context is off-label. That means your clinician is considering it outside those original indications and takes responsibility for deciding whether that use is appropriate for you.
Any time, before your renewal date. No phone calls required.